Brief: Cnm-Au8 Associated With Delayed Time To Key Clinical Progression Events At Six Months In Als Platform Trial

Clene

09/03/2023 12:27

March 9 (Reuters) - Clene Inc.  CLNN.O :
    * CNM-AU8® ASSOCIATED WITH DELAYED TIME TO KEY CLINICAL
PROGRESSION EVENTS AT SIX MONTHS SUPPORTING A SURVIVAL BENEFIT
IN THE HEALEY ALS PLATFORM TRIAL
    * CNM-AU8® ASSOCIATED WITH DELAYED TIME TO KEY CLINICAL
PROGRESSION EVENTS AT SIX MONTHS SUPPORTING A SURVIVAL BENEFIT
IN THE HEALEY ALS PLATFORM TRIAL
    * CLENE INC.: CNM-AU8 TREATMENT WAS WELL-TOLERATED WITHOUT
SIGNIFICANT SAFETY CONCERNS
    * CLENE INC.: CNM-AU8 ASSOCIATED WITH A 98% LOWER RISK OF
DEATH OR
PERMANENT ASSISTED VENTILATION
    * CLENE INC.: CNM-AU8 ASSOCIATED WITH A 74% LOWER RISK OF
FEEDING
TUBE PLACEMENT
    * CLENE INC.: CNM-AU8 ASSOCIATED WITH A 63% LOWER RISK OF
INITIATION OF ASSISTED VENTILATION

Source text for Eikon:  ID:nGNXZxFGG 
Further company coverage:  CLNN.O 

 ((Reuters.Briefs@thomsonreuters.com;))